Evaluación de la preferencia de los pacientes con enfermedad por reflujo gastroesofágico y disfagia por el tratamiento con comprimidos bucodispersables de lansoprazol

[1]  E. Márquez-Contreras,et al.  Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care , 2008 .

[2]  J. Ponce,et al.  Acceptability of Lansoprazole Orally Disintegrating Tablets in Patients with Gastro-Oesophageal Reflux Disease , 2007, Clinical drug investigation.

[3]  J. Ponce,et al.  Trastornos de la deglución: un reto para el gastroenterólogo , 2007 .

[4]  G. Song,et al.  Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. , 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[5]  E. Kuipers,et al.  Persistence and adherence to proton pump inhibitors in daily clinical practice , 2006, Alimentary pharmacology & therapeutics.

[6]  D. Levine,et al.  Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  P. Malfertheiner,et al.  Lansoprazole Fast Disintegrating Tablet: A New Formulation for an Established Proton Pump Inhibitor , 2003, Digestion.

[8]  Bown Rl.  An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. , 2002 .

[9]  J. Ponce,et al.  Guía de práctica clínica sobre el manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE) , 2002 .

[10]  A. Hungin,et al.  Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.